NCT04722133View on ClinicalTrials.gov

Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Interventions
DRUG

HERZUMA+mFOLFOX

Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks

Trial Locations (1)

Unknown

Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT04722133 - Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy | Biotech Hunter | Biotech Hunter